TFFP vs. SONN, PTIX, ADXS, CING, FWBI, HOTH, GNPX, XBIO, SNPX, and KTRA
Should you be buying TFF Pharmaceuticals stock or one of its competitors? The main competitors of TFF Pharmaceuticals include Sonnet BioTherapeutics (SONN), Protagenic Therapeutics (PTIX), Ayala Pharmaceuticals (ADXS), Cingulate (CING), First Wave BioPharma (FWBI), Hoth Therapeutics (HOTH), Genprex (GNPX), Xenetic Biosciences (XBIO), Synaptogenix (SNPX), and Kintara Therapeutics (KTRA). These companies are all part of the "pharmaceutical preparations" industry.
TFF Pharmaceuticals (NASDAQ:TFFP) and Sonnet BioTherapeutics (NASDAQ:SONN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, valuation, institutional ownership, dividends, community ranking, risk and analyst recommendations.
15.3% of TFF Pharmaceuticals shares are held by institutional investors. Comparatively, 9.5% of Sonnet BioTherapeutics shares are held by institutional investors. 5.6% of TFF Pharmaceuticals shares are held by insiders. Comparatively, 2.0% of Sonnet BioTherapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
TFF Pharmaceuticals received 50 more outperform votes than Sonnet BioTherapeutics when rated by MarketBeat users. However, 80.95% of users gave Sonnet BioTherapeutics an outperform vote while only 67.68% of users gave TFF Pharmaceuticals an outperform vote.
In the previous week, TFF Pharmaceuticals and TFF Pharmaceuticals both had 1 articles in the media. Sonnet BioTherapeutics' average media sentiment score of 0.22 beat TFF Pharmaceuticals' score of 0.00 indicating that Sonnet BioTherapeutics is being referred to more favorably in the news media.
TFF Pharmaceuticals has a beta of 1.44, suggesting that its stock price is 44% more volatile than the S&P 500. Comparatively, Sonnet BioTherapeutics has a beta of 0.62, suggesting that its stock price is 38% less volatile than the S&P 500.
TFF Pharmaceuticals presently has a consensus target price of $72.00, suggesting a potential upside of 3,312.32%. Sonnet BioTherapeutics has a consensus target price of $30.00, suggesting a potential upside of 1,569.73%. Given TFF Pharmaceuticals' higher probable upside, equities research analysts plainly believe TFF Pharmaceuticals is more favorable than Sonnet BioTherapeutics.
TFF Pharmaceuticals has a net margin of -2,897.95% compared to Sonnet BioTherapeutics' net margin of -11,187.19%. TFF Pharmaceuticals' return on equity of -163.14% beat Sonnet BioTherapeutics' return on equity.
Sonnet BioTherapeutics has lower revenue, but higher earnings than TFF Pharmaceuticals.
Summary
TFF Pharmaceuticals beats Sonnet BioTherapeutics on 9 of the 14 factors compared between the two stocks.
Get TFF Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for TFFP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TFFP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
TFF Pharmaceuticals Competitors List
Related Companies and Tools
